EU HTA Publication Digest: Advancing cooperation in Health Technology Assessment in Europe: insights from the EUnetHTA 21 project amidst the evolving legal landscape of European HTA

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-Based Publications Digest. In a recent publication, Chu et al. conducted a systematic review to develop an admission criterion framework for high-cost medical consumables in governmental hospitals. The study was carried out in a multi-country context and established a framework with seven first-level and 23 second-level indicators, highlighting the primacy of “Clinical Benefit,” followed by “Economic Value,” and “Organizational Impact.” This framework helps decision-makers ensure both efficient resource allocation and robust clinical outcomes.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Cimprich et al. discussed strategies of regulatory actors, particularly market authorization agencies, health technology assessment agencies, and health care procurement agencies, for integrating environmental sustainability requirements into the regulation of medicines and medical devices. Their analysis, contextualized within diverse healthcare settings, reveals significant untapped possibilities for strengthening regulatory frameworks to mitigate the ecological footprint of health technologies.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, van den Broek-Altenburg et al. reviewed 20–25 years of economic value assessment approaches in healthcare, highlighting the growing focus on individual preferences over broad societal metrics in value-based care models. The study underscores the complexities of incorporating patient-specific preferences into economic evaluations, and addresses recognized limitations of QALY measures. The authors discussed emerging alternative valuation frameworks that could influence future policy and reimbursement decision-making.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent study, Puñal-Riobóo et al. developed a standardized minimum outcome dataset for left ventricular assist device (LVAD) registries to address key evidence gaps and meet the needs of Health Technology Assessment (HTA) bodies and healthcare professionals. Building on prior HTA findings from EUnetHTA, the authors conducted a structured three-round Delphi process with an expert panel of cardiologists to assess the relevance of various outcome measures. The consensus resulted in 18 key outcomes and 47 variables across seven healthcare domains, strengthening the reliability of real-world evidence and supporting more informed clinical and policy decisions.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Schweitzer et al. explored the suitability of the current German HTA dossier templates for the impending EU joint clinical assessment (JCA). The study examined how extensively safety endpoint and subgroup analyses in German dossiers were actually considered by IQWiG and the G-BA. The authors found that the current German HTA templates significantly increased the workload of HTA developers while leaving many reported outcomes unconsidered by IQWiG and G-BA. To mitigate duplicative efforts and ensure prompt availability of medicinal products in line with the EU HTA Regulation framework, the authors recommend well-defined dossier requirements, early consultations, and proactive engagement with HTA developers.